EOLS Expense Breakdown
Evolus, Inc. (EOLS). Quarter ended 2026-06-30 · each product line is listed as filed.
- 2026-06-30: Reportable $26.90M.
- 2025-06-30: Reportable $24.07M.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $26.90M |
| 2025-06-30 | $24.07M |
Depreciation, Depletion and Amortization, Nonproduction: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $1.53M |
| 2025-06-30 | $932.00K |
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | -$154.00K |
| 2025-06-30 | $53.00K |
Research and Development Expense (Excluding Acquired in Process Cost): each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $1.89M |
| 2025-06-30 | $1.84M |
Selling, General and Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $57.05M |
| 2025-06-30 | $56.67M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |